Quotables
"Everyone acquainted with the subject will recognize it as a conspicuous failure."
Henry Morton, president of the Stevens Institute of Technology ; Said in 1880 about the light bulb
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8048419 | Extracorporeal cell-based therapeutic device and delivery system Extracorporeal cell-based therapeutic devices and delivery systems are disclosed which provide a method for therapeutic delivery of biologically active molecules produced by living cells in response to a dynamic physiologic environment. Exemplary designs are disclos... | 11/01/2011 |
| 7744883 | Method for reducing the number of unwanted molecules in blood The present invention provides a method, and resulting product, for the removal of unwanted molecules from a host's blood using a one-step procedure. The unwanted molecules may be anti-A blood protein and/or anti-B blood protein antibodies that would otherwise cause... | 06/29/2010 |
| 7425619 | FcγRIIB specific antibodies and methods of use thereof The present invention relates to antibodies or fragments thereof that specifically bind FcγRIIB, particularly human FcγRIIB, with greater affinity than said antibodies or fragments thereof bind FcγRIIA, particularly human FcγRIIA. The invention provides methods ... | 09/16/2008 |
| 7364656 | Triazine-based detoxification agents and their use An affinity ligand-matrix conjugate comprises the matrix and conjugated thereto by the group Z, a ligand having general formula (I): wherein one X is N and the other X is N, CCL or CCn; A1 and A2 are e... | 04/29/2008 |
| 7309488 | Adsorbents for dilated cardiomyopathy An adsorbent which comprises a water-insoluble carrier and a compound, which is immobilized on said carrier, having a binding affinity for an antibody against β1-adrenoceptor and/or an antibody against M2 muscarinic receptor exhibits a remarkably large adsorptive c... | 12/18/2007 |
| 7300633 | Specimen collection container The present invention recognizes that sample handling devices, particularly those used for testing for substances of abuse, do not allow for a separation of the bulk sample from a sample thereof to be tested. The present invention provides such a device and methods ... | 11/27/2007 |
| 7291122 | Hemofiltration methods for treatment of diseases in a mammal A hemofiltration system and method to treat an Inflammatory Mediator Related Disease in a mammal, including chronic and acute diseases, include a hemofilter and an adsorptive device. The hemofilter removes ultrafiltrate from a blood stream extracted from the mammal ... | 11/06/2007 |
| 7279542 | Polymeric particles and fragrance delivery systems Polymeric micro- and nano-capsules formed of a spherical single hydrophobic polymer, chemically functionalised at their surface so as to comprise hydrophilic moieties thereon are disclosed. The capsules are susceptible of absorbing a perfume and of being optionally ... | 10/09/2007 |
| 7270959 | Specimen collection container The present invention recognizes that sample handling devices, particularly those used for testing for substances of abuse, do not allow for a separation of the bulk sample from a sample thereof to be tested. The present invention provides such a device and methods ... | 09/18/2007 |
| 7259012 | Use of oxidized lipoproteins for differentiation of precursor cells into mature dendritic cells The invention concerns a method for differentiating precursor cells into mature dendritic cells, comprising placing the precursor cells in a medium suitable for their differentiation and adding to the medium, in a predetermined amount, at least one fraction of oxidi... | 08/21/2007 |
| 7226429 | Method for removal of viruses from blood by lectin affinity hemodialysis The present invention relates to a method for using lectins that bind to pathogens having high mannose surface glycoproteins or fragments thereof which contain high mannose glycoproteins, to remove them from infected blood or plasma in an extracorporeal setting. Acc... | 06/05/2007 |
| 7207964 | Apparatus and method for down-regulating immune system mediators in blood A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately... | 04/24/2007 |
| 7201901 | Capture, concentration and quantitation of abnormal prion protein from biological fluids using depth filtration Methods for producing biological solutions such as immunoglobulins and in particular anti-D immunoglobulin substantially free of abnormal prion protein resulting therefrom. Specifically provided are methods for aggregation of prions and depth filtration of the biolo... | 04/10/2007 |
| 7202045 | Detection and treatment of cancers of the lung The present invention relates to compositions and methods for cancer therapies and diagnostics, including but not limited to, cancer markers. In particular, the present invention provides tumor antigens associated with specific cancers and diagnostic assays for the ... | 04/10/2007 |
| 7201730 | Device and method for reducing inflammatory mediators in blood A method and apparatus for preventing and treating septicemia in patient blood is provided. The extracorporeal system includes an antimicrobial device to inactivate at least 99% of bloodborne microorganisms, a hemoconcentrator/filtration unit to remove approximately... | 04/10/2007 |
| 7160723 | Cell separation compositions and methods The invention provides compositions and methods for cell separation. These reagents and techniques specifically agglutinate cells via surface antigen recognition and can be used to recover even rare cell types in high yield. ... | 01/09/2007 |
| 7153945 | Peptide, novel adsorbent, adsorption unit and adsorption method The present invention provides an adsorbent, adsorption unit, and an adsorption method which make it possible to selectively adsorb an immunoglobulin and/or an immune complex present in a body fluid (for example, blood, plasma, etc.) efficiently without pretreating ... | 12/26/2006 |
| 7083787 | Yeast-dendritic cell vaccines and uses thereof Disclosed is a vaccine that includes a dendritic cell loaded with a yeast vehicle and antigen. Also disclosed are methods of making the vaccine and using the vaccine to elicit cellular and humoral immune responses in a mammal. Additionally, a method to elicit an imm... | 08/01/2006 |
| 7056507 | Adsorbent for eliminating hepatitis C virus, adsorber, and adsorption method An adsorbent for removing hepatitis C virus which has the ability to adsorb HCV particles, particularly immune-complex HCV particles, from a patient's body blood safely and with high efficiency and high selectivity for enhancing the efficacy of interferon therapy, a... | 06/06/2006 |
| 7022322 | treatment of cardiomyopathy by removal of autoantibodies Immunoapheresis treatment for cardiomyopathy comprises passing the patient's plasma over a column having coupled thereto a specific ligand for human immunoglobulin, thereby removing a significant portion of the immunoglobulin from the patient's plasma, and then rein... | 04/04/2006 |
| 7014854 | Method for retarding or precluding Alzheimer's dementia A method for treating a condition related to the development of Alzheimer's disease (AD) is disclosed. The method involves the removal of circulating autoantibodies of a biochemical marker or markers, specifically human glial fibrillary acidic protein (GFAP) and gly... | 03/21/2006 |
| 6994854 | Protective epitopes of adenyl cyclase-haemolysin (AC-Hly), their application to the treatment or to the prevention of bordetella infections The subject of the invention is amino acid sequences of the AC-Hly from B. pertussis, B. parapertussis and/or B. bronchiseptica, carrying epitopes capable of inducing a protective immune response against infection by Bordetella. The subject of t... | 02/07/2006 |
| 6984383 | Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins The invention relates to a humanized anti-B7-2 antibody that comprises a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also pertains to methods of treatment for various autoimmune diseases, transplant r... | 01/10/2006 |
| 6969616 | Enterotoxin adsorbent, method of adsorptive removal, and adsorption apparatus The present invention is directed to an enterotoxin adsorbent comprising a compound having a log P (P denotes a partition coefficient in an octanol-water system) value of not less than 2.50 as immobilized on a water-insoluble carrier. ... | 11/29/2005 |
| 6951644 | Adsorbent for peptidoglycan and method and apparatus for adsorptively removing peptidoglycan An adsorbent for peptidoglycan which comprises an water-insoluble porous material having an amino group and having a molecular weight of exclusion limit of at least 50,000, and a method for removing peptidoglycan by adsorption, which comprises a step of contacting t... | 10/04/2005 |
| 6939543 | Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria The present invention encompasses monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal... | 09/06/2005 |
| 6924361 | Phosphopeptide-specific antibodies that are activity specific; methods of production and antibody uses This invention relates to growth regulatory proteins expressed in various disease states, especially receptor tyrosine kinases and similar growth factor receptors. Prior to the Applicants invention, it was not clear that specific antibodies could be generated that r... | 08/02/2005 |
| 6916419 | Device for removal of prions from blood, plasma and other liquids Devices such as flow through columns, substrates such as spherical polymer beads, and methods of using such to remove prions from any liquid sample are disclosed. A surface of a substrate is coated with a prion complexing agent, such as a salt of phosphotungstic aci... | 07/12/2005 |
| 6881408 | Immunoadsorber for use in sepsis therapy The invention relates to immunoadsorbers for use in sepsis therapy, in particular for removal of complement factors and lipopolysaccharides (LPS) and, if need be, further sepsis mediators such as TNF and interleukins from body fluids, methods for their production an... | 04/19/2005 |
| 6878127 | Devices, systems, and methods for reducing levels of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood Devices, systems, and methods reduce levels of pro-inflammatory or anti-inflammatory stimulators or mediators in blood by selective adsorption. The devices, systems, and methods are useful in situations where abnormal levels of or unregulated or excessive interactio... | 04/12/2005 |
| 6866846 | Patient-specific immunoadsorbers for the extracorporeal apheresis and methods for their preparation A process for preparing a patient-specific immunoadsorber, which comprises (i) extracting a body fluid from a patient having an immunopathological condition, the fluid containing immune complexes that are relevant to that immunopathological condition, (ii) contactin... | 03/15/2005 |
| 6846637 | Fas peptides and antibodies for modulating apoptosis Anti-Fas (APO-1, CD95) autoantibodies arm found in human s, which antibodies arm biologically functional. Peptide fragments of Fas recognized by such antibodies, and antibodies specific for such peptides, inhibit or promote apoptosis and cellular proliferation. Assa... | 01/25/2005 |
| 6803036 | Use of cytokines, cells and mitogens to inhibit graft versus host disease The field of the invention is generally related to pharmaceutical agents useful in treating graft-versus-host disease (GVHD) in patients that have received allogenic bone marrow transplants. ... | 10/12/2004 |
| 6756361 | Enterococcus antigens and vaccines A majority of E. faecalis and E. faecium clinical isolates fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. The Enterococcus antigens are readily obtained from strains of E. faecalis ... | 06/29/2004 |
| 6740493 | Bone precursor cells: compositions and methods Disclosed are compositions of bone precursor cells and methods for their preparation and use. Bone precursor cells are cells which are not hematopoietic and which can differentiate into osteoblasts upon exposure to a bone growth factor and deposit calcium into the e... | 05/25/2004 |
| 6723318 | Targeting of biomolecules The present invention provide methods to improve the treatment of cancer in mammals, including ovarian cancer, where intraperitoneal administration of cytotoxic medical agents or immunoconjugates are utilized. The invention provides means of substantially reducing t... | 04/20/2004 |
| 6713252 | Method for removing and reducing hepatitis C virus Described is a method of removing and reducing HCV from the blood of an HCV-infected patient, which comprises carrying out, once a day for at least 5 straight days, a treatment of bringing the blood into contact with an adsorptive carrier having a higher affinity fo... | 03/30/2004 |
| 6676622 | Extracorporeal affinity adsorption methods for the treatment of atherosclerosis, cancer, degenerative and autoimmune diseases Extracorporeal affinity adsorption treatments which are aimed at the substantial removal of two or more compounds that are etiological in the pathogenesis of diseases in man provide effective therapeutic intervention means for these diseases. The methods ... | 01/13/2004 |
| 6630315 | Process for preparing major histocompatibility antigen class II protein and materials in which the same is bound This invention provides a process for producing major histocompatibility antigen class II protein (hereinafter referred to as "MHC class II" for short) which occurs on the surfaces of antigen-presenting cells and the like, and MHC class II-bound materials... | 10/07/2003 |
| 6630142 | Method of treating fibroproliferative disorders Materials and methods for reducing cell proliferation or extracellular matrix production in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf4 antagonist in combin... | 10/07/2003 |
